A pilot randomized controlled trial of the feasibility and safety of a combined Epigallocatechin-3-gallate (EGCG) and vitamin C nutraceutical in pre-frail and frail older cancer survivors: Results from the ReFOCUS1 trial.
Nikesha Gilmore, Richard F Dunne, Charles Kamen, Beverly Canin, Michael Sohn, Fergal Fleming, Efrat Dotan, Goldie Smith Byrd, Lelaina Nagle, Jihane Jean, Patricia Fenton, Carla Falkson, Sindhuja Kadambi, Ajay Dhakal, Wenjia Wang, Chunkit Fung, Erika Ramsdale, Jason Zittel, Luke Peppone, Supriya Mohile, Michelle Janelsins
J Geriatr Oncol 18(3) 104694
摘要
摘要
INTRODUCTION: Frailty is common among older cancer survivors and is associated with increased morbidity and mortality. Inflammation and oxidative stress are key biological mechanisms underlying frailty and are markers of these processes representing important therapeutic targets for interventions aimed at reducing frailty. Epigallocatechin gallate (EGCG), a green tea polyphenol with anti-inflammatory and antioxidant properties, combined with vitamin C, may be a novel approach to target these biological processes implicated in frailty. Although the combination of EGCG with vitamin C has been examined in pharmacokinetic studies conducted in non-cancer populations, its safety and feasibility have not been evaluated among older cancer survivors. MATERIALS AND METHODS: Older adults (age ≥ 65) with stage I-III solid cancer, within 10 years of curative intent treatment, and Fried's Frailty Score (FFS) ≥ 2 were randomized to the intervention group (800 mg EGCG +250 mg vitamin C daily) or control group (usual care) for 12 weeks. Feasibility was assessed by rates of recruitment, retention, and adherence to intervention. Safety was assessed via adverse events (AEs), graded using NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0. FFS was assessed at baseline and post-intervention with participants categorized as non-frail (FFS = 0), pre-frail (FFS = 1-2), or frail (FFS = 3-5). RESULTS: Out of 64 patients approached, 25 consented to participate, 19 met eligibility criteria, and 14 randomized. All (14/14) participants (mean age = 74.6 years; range 65-90) completed the study, and 86% (6/7) in the intervention group were adherent. A total of 35 AEs were reported (control: n = 9 [7 Grade 1, 2 Grade 2]; intervention: n = 26 [23 Grade 1, 2 Grade 2, 1 Grade 3]). Ten of 14 participants (71%) reported at least one AE (control: 4/7 [57%]; intervention: 6/7 [86%]). From baseline to post-intervention, FFS status improved in one control group participant (frail to pre-frail) and two intervention group participants (pre-frail to non-frail). DISCUSSION: Recruitment of pre-frail and frail older cancer survivors to a 12-week EGCG plus vitamin C intervention trial is feasible. The intervention was associated with predominantly Grade 1 AEs. Preliminary findings support further evaluation in a larger study. These findings are descriptive and should be interpreted in the context of the small sample size.
KM 提取结果
0 个 Figure · 0 个 KM 面板